Aerpio Initiates Phase 1b Clinical Trial of Topical Ocular Formulation of AKB-9778 for Primary Open Angle Glaucoma
CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced dosing of the first subject in a Phase 1b trial of a topical ocular formulation of AKB-9778 in development for treatment of primary open angle glaucoma (POAG). The Phase 1 study is a double-masked, multiple-ascending dose trial and will enroll four cohorts of 12 subjects. Subj